George C Eckert Ii

Array ( [id] => 16901141 [patent_doc_number] => 20210180057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => MODULATORS OF ENaC EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/759908 [patent_app_country] => US [patent_app_date] => 2018-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -91 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15696813 [patent_doc_number] => 10604574 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Oncolytic viral delivery of therapeutic polypeptides [patent_app_type] => utility [patent_app_number] => 16/170764 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 56 [patent_no_of_words] => 39342 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16170764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14564177 [patent_doc_number] => 20190209695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Pharmaceutical Compositions for High-Capacity Targeted Delivery [patent_app_type] => utility [patent_app_number] => 16/166875 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16166875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13902373 [patent_doc_number] => 20190040391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => METHODS AND COMPOSITIONS FOR SELECTION OF FUNCTIONAL OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/165267 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14762 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328286 [patent_doc_number] => 11633503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Delivery of oligonucleotide-functionalized nanoparticles [patent_app_type] => utility [patent_app_number] => 16/160196 [patent_app_country] => US [patent_app_date] => 2018-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 23367 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16160196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915803 [patent_doc_number] => 20210188895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => SINGLE-STRANDED NUCLEIC ACID MOLECULE, AND PRODUCTION METHOD THEREFOR [patent_app_type] => utility [patent_app_number] => 16/755824 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17953676 [patent_doc_number] => 11479770 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-25 [patent_title] => Use of p38 inhibitors to reduce expression of DUX4 [patent_app_type] => utility [patent_app_number] => 16/753664 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 32 [patent_no_of_words] => 23777 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 120 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16753664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14761913 [patent_doc_number] => 10392341 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-08-27 [patent_title] => Compounds and compositions for intracellular delivery of therapeutic agents [patent_app_type] => utility [patent_app_number] => 16/148822 [patent_app_country] => US [patent_app_date] => 2018-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 70176 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16148822 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14040713 [patent_doc_number] => 20190076463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => NOVEL RNA CONSTRUCT AND METHODS OF USE THEREOF FOR ENHANCING THE THERAPEUTIC EFFECTS OF CYTOTOXIC CELLS AND STEM CELLS [patent_app_type] => utility [patent_app_number] => 16/147844 [patent_app_country] => US [patent_app_date] => 2018-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8877 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16147844 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581881 [patent_doc_number] => 20190218549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE [patent_app_type] => utility [patent_app_number] => 16/142953 [patent_app_country] => US [patent_app_date] => 2018-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69263 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16142953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15711597 [patent_doc_number] => 20200102564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms [patent_app_type] => utility [patent_app_number] => 16/141464 [patent_app_country] => US [patent_app_date] => 2018-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16141464 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16157231 [patent_doc_number] => 20200216848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-09 [patent_title] => VARIANT RNAi [patent_app_type] => utility [patent_app_number] => 16/649042 [patent_app_country] => US [patent_app_date] => 2018-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27557 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -124 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16649042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14310333 [patent_doc_number] => 20190144870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE [patent_app_type] => utility [patent_app_number] => 16/137046 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 88138 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16137046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15650273 [patent_doc_number] => 20200087666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => COMPOUNDS TARGETING LONG NON CODING RNA FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/130018 [patent_app_country] => US [patent_app_date] => 2018-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21338 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16130018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336574 [patent_doc_number] => 10787519 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Nucleic acid-polypeptide compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 16/128428 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 136 [patent_figures_cnt] => 184 [patent_no_of_words] => 96233 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 158 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128428 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369107 [patent_doc_number] => 10800848 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Nucleic acid-polypeptide compositions and uses thereof [patent_app_type] => utility [patent_app_number] => 16/128417 [patent_app_country] => US [patent_app_date] => 2018-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 136 [patent_figures_cnt] => 184 [patent_no_of_words] => 96271 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16128417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18428929 [patent_doc_number] => 11674140 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Compositions and methods for treating facioscapulohumeral dystrophy [patent_app_type] => utility [patent_app_number] => 16/643772 [patent_app_country] => US [patent_app_date] => 2018-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 54 [patent_no_of_words] => 12536 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16643772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14159187 [patent_doc_number] => 20190106696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-11 [patent_title] => CHIRAL DESIGN [patent_app_type] => utility [patent_app_number] => 16/109638 [patent_app_country] => US [patent_app_date] => 2018-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 106071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16109638 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16476495 [patent_doc_number] => 10851424 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-01 [patent_title] => MicroRNA profiling for diagnosis of dysplastic nevi and melanoma [patent_app_type] => utility [patent_app_number] => 15/999033 [patent_app_country] => US [patent_app_date] => 2018-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 20587 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15999033 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16792886 [patent_doc_number] => 20210122703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-29 [patent_title] => LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/638731 [patent_app_country] => US [patent_app_date] => 2018-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16638731 [rel_patent_id] =>[rel_patent_doc_number] =>)